CD8A and cancer: The exact contribution of CD4+ versus CD8+ T cells to the proatherogenic effects of immune checkpoint inhibitors is still unclear, but understanding their specific roles in mediating vascular inflammation and injury may help to design strategies to antagonize these effects in patients treated with checkpoint inhibitors in cancer therapy.